FDA said to end speedy drug review program while Compass Pathways submits FDA New Drug Application for psilocybin; Feds commit $25 million for ibogaine and “psychotropic” research
Storyflo cites this publisher's work in our daily briefings, but no commentary on this specific piece has been published yet. Read the original on the publisher's site, or browse our daily briefings for related coverage.